Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome.
Ruiz-Pablos, Manuel, Paiva, Bruno, Montero-Mateo, Rosario et al. · Frontiers in immunology · 2021 · DOI
Quick Summary
This review examines whether Epstein-Barr virus (EBV), a common virus that causes mononucleosis, might play a role in causing ME/CFS in some patients. The researchers found that certain people may have genetic traits that make them more vulnerable to EBV, and in these individuals, the virus might hide from the immune system in a way that leads to ME/CFS symptoms. They suggest that antiviral treatments targeting EBV could potentially help some ME/CFS patients.
Why It Matters
Understanding whether EBV plays a causal role in ME/CFS could open pathways to targeted treatments for a subset of patients and help explain why some people develop this debilitating disease after viral infection. This work may guide future clinical trials testing antiviral therapies and inform genetic screening to identify vulnerable individuals.
Observed Findings
Multiple studies have documented altered cellular immunity and augmented Th2 response in ME/CFS patients.
EBV has been identified as a risk factor in a subset of ME/CFS patients.
ME/CFS patients show similarities to EBV-associated autoimmune diseases in terms of expanded EBV-infected cells and increased anti-EBV antibodies.
Some ME/CFS patients demonstrate poor CD4 T cell immunity to mitogens and specific antigens.
Inferred Conclusions
A subgroup of ME/CFS patients may carry HLA alleles (DRB1 and DQB1) that confer greater susceptibility to EBV infection.
EBV-infected cells may evade immune surveillance in genetically predisposed individuals, leading to immunodeficiency and ME/CFS symptoms.
Does EBV directly cause ME/CFS through immune evasion, or is it one of multiple triggers in different patient subgroups?
Which specific HLA alleles confer EBV susceptibility in ME/CFS patients, and how prevalent is this genetic pattern?
Would antiviral therapies targeting EBV be effective in improving ME/CFS symptoms, and in which patient populations?
What This Study Does Not Prove
This review does not prove that EBV causes ME/CFS in all or most patients—only that it may be relevant in a subset. The evidence reviewed is inconclusive about the direction of causality, and the proposal for EBV-specific HLA associations remains hypothetical and requires experimental validation. The study does not establish effective treatments.